Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities ... was initiated Friday by the FDA and CDC while the two federal agencies ...

The FDA said it will conduct an updated benefit-risk assessment for the use of Ixchiq in the 60-and-up age bracket and that both the agency and the CDC will continue monitoring safety reports for ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued advisories late last week regarding the vaccine Ixchiq, developed by Valneva. Chikungunya is ...

17 serious adverse events, including two deaths, reported among adults 62–89 who received the Ixchiq vaccine. Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities ... was initiated Friday by the FDA and CDC while the two federal agencies ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...